MX2009012429A - Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma. - Google Patents

Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma.

Info

Publication number
MX2009012429A
MX2009012429A MX2009012429A MX2009012429A MX2009012429A MX 2009012429 A MX2009012429 A MX 2009012429A MX 2009012429 A MX2009012429 A MX 2009012429A MX 2009012429 A MX2009012429 A MX 2009012429A MX 2009012429 A MX2009012429 A MX 2009012429A
Authority
MX
Mexico
Prior art keywords
prevention
ppar
gamma agonists
adverse effect
effect due
Prior art date
Application number
MX2009012429A
Other languages
English (en)
Spanish (es)
Inventor
Menotti Calvani
Stefania D Iddio
Paola Benatti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2009012429A publication Critical patent/MX2009012429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
MX2009012429A 2007-05-24 2008-04-28 Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma. MX2009012429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108801 2007-05-24
PCT/EP2008/055171 WO2008141897A1 (en) 2007-05-24 2008-04-28 Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists

Publications (1)

Publication Number Publication Date
MX2009012429A true MX2009012429A (es) 2009-12-09

Family

ID=38668873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012429A MX2009012429A (es) 2007-05-24 2008-04-28 Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma.

Country Status (10)

Country Link
US (1) US20100305204A1 (enExample)
EP (1) EP2162127A1 (enExample)
JP (1) JP2010527952A (enExample)
KR (1) KR20100017460A (enExample)
CN (1) CN101677983B (enExample)
AU (1) AU2008253134A1 (enExample)
BR (1) BRPI0812306A2 (enExample)
CA (1) CA2687154A1 (enExample)
MX (1) MX2009012429A (enExample)
WO (1) WO2008141897A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
KR102072075B1 (ko) * 2018-06-21 2020-01-31 울산과학기술원 TRIM25을 유효성분으로 함유하는 PPARγ 분해용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
DE69942672D1 (de) * 1998-12-17 2010-09-23 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
CN1812988A (zh) * 2003-05-13 2006-08-02 斯索恩有限公司 制备噻唑烷二酮衍生物的方法及其化合物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient

Also Published As

Publication number Publication date
CA2687154A1 (en) 2008-11-27
AU2008253134A1 (en) 2008-11-27
CN101677983A (zh) 2010-03-24
US20100305204A1 (en) 2010-12-02
EP2162127A1 (en) 2010-03-17
JP2010527952A (ja) 2010-08-19
WO2008141897A1 (en) 2008-11-27
CN101677983B (zh) 2012-12-26
BRPI0812306A2 (pt) 2014-11-25
KR20100017460A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
MY148253A (en) Azaadamantane derivatives and methods of use
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
MX2010010135A (es) Derivados de hidroximoil-tetrazol fungicidas.
UA105229C2 (uk) Фармацевтичний склад
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2010007677A (es) Derivados de hidroximoil-tetrazol como fungicidas.
PH12013500695A1 (en) Pharmaceutical compositions containing a dgat1 inhibitor
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
TW200612958A (en) Substituted imidazole derivatives
TW200942524A (en) Novel aminomethyl benzene derivatives
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010076009A8 (de) Pyrimidinderivate und ihre verwendung zur bekämpfung unerwünschten pflanzenwachstums
MX2009008028A (es) Agentes antiparasitarios.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
MX336392B (es) Derivados de hidroximoil-heterociclos fungicidas.
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
MX372773B (es) Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди